Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma, Multiple Myeloma in Relapse
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine if UF-KURE-BCMA (B-Cell Maturation Antigen) chimeric antigen receptor T cells (CAR-T cells) can be used to treat relapsed or treatment refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT06698744
- Testing
- UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- David Wald
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
RATIONALE: Bone marrow from donors may be able to treat patients with severe aplastic anemia and patients whose bodies have rejected previous bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00005852
- Testing
- anti-thymocyte globulin, filgrastim, muromonab-CD3
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Refractory Multiple Myeloma
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Pomalidomide and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT01212952
- Testing
- pomalidomide, bortezomib, dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Relapsed/Refractory Multiple Myeloma
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic…
- Trial name
- NCT04635735
- Testing
- Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the…
- Trial name
- RedirecTT-1 (NCT04586426)
- Testing
- Talquetamab, Teclistamab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Relapse
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to…
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging
- Trial name
- NCT05911321
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
Refractory Multiple Myeloma
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in…
- Trial name
- NCT03731832
- Testing
- MLN9708, Pomalidomide 4 MG Oral Capsule, Dexamethasone
- Where
- 11 sites in Germany
- Volunteers
- 66 people
- Sponsor
- GWT-TUD GmbH
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT00920855
- Testing
- bendamustine, bortezomib
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cephalon
Multiple Myeloma
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
This is a phase II study, open-label, single institution trial of pomalidomide in GEP-defined, high-risk relapsing/refractory multiple myeloma. Prior therapy must have included lenalidomide.
- Trial name
- NCT01177735
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of Arkansas
Multiple Myeloma
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event)…
- Trial name
- NCT06566547
- Testing
- GR1803 injection
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Neoplasms, Plasma Cell, Neoplasms by Histologic Type
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple…
- Conditions
- Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders
- Trial name
- NCT06271252
- Testing
- OriCAR-017
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- OriCell Therapeutics Co., Ltd.
Multiple Myeloma and Plasma Cell Neoplasm, Pain
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells.
- Trial name
- NCT00482378
- Testing
- Pamidronate, Zoledronic acid, Sm 153 lexidronam
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Relapsed or Refractory Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or…
- Trial name
- MajesTEC-9 (NCT05572515)
- Testing
- Teclistamab, Pomalidomide, Bortezomib
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 614 people
- Sponsor
- Janssen Research & Development, LLC
Refractory Multiple Myeloma
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of…
- Trial name
- EMBRACE (NCT06421675)
- Testing
- Elranatamab injection
- Where
- 6 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Multiple Myeloma
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: Trametinib Dabrafenib
- Trial name
- NCT03091257
- Testing
- Dabrafenib, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Relapsed/Refractory Multiple Myeloma
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
The purpose of this study was to evaluate the effects of daratumumab with dexamethasone (DaraD) in subjects with relapsed or refractory multiple myeloma and renal impairment.
- Trial name
- DARE (NCT03450057)
- Testing
- Daratumumab with dexamethasone
- Where
- Greece
- Volunteers
- 38 people
- Sponsor
- Hellenic Society of Hematology
Neoplasms, Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies
- Conditions
- Neoplasms, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma, Refractory
- Trial name
- CARLOTTA01 (NCT05836896)
- Testing
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Technische Universität Dresden
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.